Gain Therapeutics' Rexaceract Shows 12-Month Disease-Modifying Potential in Parkinson's Trial
Event summary
- Gain Therapeutics' Phase 1b open-label extension data for rexaceract demonstrated stabilization of MDS-UPDRS motor scores over 12 months in 12 evaluable Parkinson’s disease patients.
- Participants with both high and low baseline levels of GluSph showed stabilization of motor scores, supporting rexaceract’s disease-modifying potential.
- No significant safety signals were observed, with a favorable tolerability profile over 12 months of dosing.
- Gain plans to submit a new Phase 2 study protocol to the FDA in the coming weeks and initiate the trial in Q1 2027.
The big picture
Gain Therapeutics' positive Phase 1b data for rexaceract positions the company as a leader in developing disease-modifying therapies for Parkinson’s disease. The stabilization of motor scores over 12 months, regardless of biomarker stratification, supports the potential of rexaceract to address the underlying biology of the disease. The upcoming Phase 2 trial will be critical in validating these findings and advancing the therapeutic paradigm beyond symptom management.
What we're watching
- Regulatory Timing
- Whether the FDA will approve the new Phase 2 protocol and the pace at which the trial will commence in Q1 2027.
- Clinical Validation
- How the stabilization of MDS-UPDRS scores will translate into long-term clinical benefits and disease modification.
- Partnering Strategy
- The potential for Gain Therapeutics to secure additional partnerships or funding based on these positive Phase 1b results.
Related topics